• Home
• About Us
• Aesthetic Medicine Training
  • Botox Training
  • Hands-On Botox and Dermal Filler Training
  • MedSpa / Aesthetic Practice Business Traininig
• Resources
  • Magazines and Periodicals
  • More Resources
  • Associations
  • Events
  • Archives
• Consumer Information

Subscribe

Experts Say Botox Has Potential to Lift Breasts Without Surgery

Oct. 26, 2009 — Add breast lifts to the growing list of potential uses for Botox. But not all experts think it’s worth the trouble.

We already know that this wrinkle eraser can help treat excessive sweating, banish frown lines, and put the brakes on certain eye muscle problems and neck spasms. But it may also give breasts a temporary, mild lift, according to experts at the annual meeting of the American Society of Plastic Surgeons (ASPS) in Seattle. Read more

               

New technique for injectable facial fillers improves comfort, recovery

DALLAS — Oct. 28, 2009 — Less pain during injections for wrinkle-fighting facial fillers. Less swelling afterward. Less time in the office waiting for anesthesia to take effect.

These and other benefits of a new injection technique that UT Southwestern Medical Center plastic surgeons are helping pioneer are outlined in the October issue of Plastic and Reconstructive Surgery. The procedure combines lidocaine with injections of facial fillers to instantly minimize the pain and allows plastic surgeons to begin injection procedures without waiting for traditional anesthesia to take effect. Read more

               

Who’s doing Medical Spa Patient Financing?

We have seen many mergers in the financial services industry, but it now looks like we have a lack of patient financing options for MedSpa patients.  It appears CareCredit has further reduced their appetite in financing minimally-invasive cosmetic procedures found in medical spas and aesthetic practices.  I’ve heard that www.chasehealthadvance.com, www.medchoicefinancial.com, www.cosmeticredit.com and www.mymedicalloan.comare the only patient financing providers left for medispas. Does anyone have any other options?  Any comments to share on any of the above patient financing companies? Read more

               

IAPAM Symposium Adds New Botox Training video to help Physicians Succeed

Physicians can now revisit the preeminent educational experience they receive while attending the IAPAM’s Aesthetic Medicine Symposium, by using the IAPAM’s 3 new clinical training DVD’s, offering focused instruction on: botox training, dermal filler training and microdermabrasion training.

The IAPAM’s Aesthetic Medicine Symposium has long offered physicians a competitive advantage through its comprehensive, hands-on, “immersion” into the field of aesthetic medicine. The IAPAM Symposium is the only program which gives physicians an opportunity to learn from two board certified dermatologists, who are true experts of the skin and cosmetic injectables. In order to ensure doctors learn the best injection techniques, the botox training is done in a medical practice, not in a hotel room chair. In addition, the symposium does not allow exhibitors, giving physicians more time for education. Read more

               

Botox lawsuit raises issues on injections

Single-use medication vials used on more than one patient.

That practice at the Endoscopy Center of Southern Nevada, public health officials have repeatedly said, contributed to the hepatitis C outbreak in the Las Vegas Valley.

Now a federal lawsuit filed in California by Las Vegas physician Ivan Goldsmith argues that sales representatives for Allergan Inc., maker of the popular anti-wrinkle drug Botox, promote multipatient use of its 50-unit or 100-unit single-use vials.

Goldsmith’s lawsuit alleges that doctors can only make a profit using Botox if they reuse the single-use vials that the drug comes in. Read more

               

New Treatment Modality for better dermal remodeling

eMatrix device pioneers Sublative Rejuvenation™ for novel skin ablation and resurfacing

Syneron Medical Ltd. (NASDAQ: ELOS), has presented a groundbreaking treatment modality at the 5-Continent-Congress for Lasers and Aesthetic Medicine in Nice on September 10th, 2009. The company introduced a new and unique treatment modality called Sublative Rejuvenation™, which answers the skin rejuvenation market’s emerging demand for optimal efficiency, minimal downtime and an affordable procedure price point. Next presentation of the Sublative Rejuvenation will be given at the 18th Congress of the Academy of Dermatology and Venereology (EADV) in Berlin, Germany. Read more

               

KYTHERA BIOPHARMACEUTICALS PRESENTS POSITIVE DATA FROM TWO PHASE 2 STUDIES WITH ATX-101 – Study results demonstrated statistically significant reduction in patients’ unwanted submental fat

KYTHERA Biopharmaceuticals, Inc. (KYTHERA) presented detailed results from two double-blind Phase 2 studies, each designed to evaluate the safety and effectiveness of ATX-101, a first-in-class injectable drug for the reduction of small volumes of fat. Top-line results from these studies, which examined use of ATX-101 for reduction of unwanted localized fat deposits under the chin (submental fat), were announced in January 2009 (http://www.kytherabiopharma.com/press_releases.html).

Kevin C. Smith MD, FAAD, FRCPC presented study results in Scientific Session at the American Society for Dermatologic Surgery (ASDS) and American Society of Cosmetic Dermatology and Aesthetic Surgery (ASCDAS) Joint Annual Meeting. A recap of the data presentation will be available online at http://www.kytherabiopharma.com/investors.html for seven days.

“ATX-101 shows promise for patients who are seeking a minimally invasive treatment for unwanted localized submental fat,” said Kevin C. Smith, a Canadian investigator in both Phase 2 studies. “The significant reduction we saw in submental fat for patients treated with ATX-101 illustrates its potential as a safe, simple prescription aesthetic product.” Read more

               

New Use For Hyaluronic Acid To Bring Increased Commercial Opportunities For Anti-Aging Industry

Nicknamed the “key to the fountain of youth”, hyaluronic acid is a transparent, gel-like substance that occurs naturally in the connective tissue of the skin, cartilage and other parts of the body. It has an extraordinary capacity to attract and retain moisture and is involved in tissue repair. In 2003 the US Food and Drug Administration (FDA) approved the use of acid injections for filling soft tissue defects such as facial wrinkles and since this stamp of approval, the anti-aging industry has never looked back. Read more

               

Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson

BURLINGTON, Mass., Oct. 16 /PRNewswire-FirstCall/ — Palomar Medical Technologies Inc. (Nasdaq: PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, today announced the termination of its agreement with Johnson & Johnson Consumer Companies Inc (”JJCC”), a Johnson & Johnson company, to develop, clinically test and commercialize home-use, light-based devices for (i) reducing or reshaping body fat including cellulite; (ii) reducing appearance of skin aging; and (iii) reducing or preventing acne. Despite Palomar having met all of its deliverables under the agreement, JJCC terminated the agreement referencing the current unfavorable economic conditions as the reason for its decision. With this decision, JJCC avoids having to make a large commercialization payment to Palomar and avoids having to commit to the significant level of funding required to successfully launch a new product into the mass market. Upon termination of the agreement, JJCC’s license to Palomar technology was terminated and all technology and intellectual property rights related to light-based devices developed under the agreement were assigned to Palomar. JJCC is also precluded from further development or commercialization of the light-based devices developed under the agreement.

Palomar will continue with the commercialization of the light-based devices developed under the agreement. In June 2009, Palomar was the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home-use, laser device for the treatment of periorbital wrinkles. OTC clearance allows this wrinkle treatment device to be marketed and sold directly to consumers without a prescription. This consumer wrinkle treatment device was developed by Palomar and completed together with JJCC. Designed specifically for use in the home and based on years of research and clinical testing, this consumer device represents a major breakthrough in the aesthetic device industry.

In order to achieve FDA clearance, numerous clinical studies with hundreds of subjects and thousands of treatments were conducted. These studies demonstrated that the laser-based device delivers comfortable, effective, skin and eye safe wrinkle treatment around the eyes.

Commenting on this development, Palomar Chief Executive Officer Joseph P. Caruso said, “We have developed game changing technology in the consumer area. Over the past few years we have developed advanced patented technology that allows us to penetrate the home market. Wrinkle treatments using OTC products are a multi-billion dollar market opportunity and we plan on entering that market with our products during the second half of next year. The current economic climate does not warrant a large scale investment in a mass market launch at this time. Therefore, we have adjusted our launch plans to be more in line with current economic conditions. In the short-term, our goal is to establish our consumer products in the market using certain specialty channels and gather the valuable information needed to fully execute our long-term strategy of a full mass market launch. Our long-term goal remains the same; to tap into the mass market using our patented technology in a number of key areas with multiple product offerings and multiple channels worldwide”.

Mr. Caruso continued, “We believe that light-based anti-aging applications will one day be an ordinary and necessary part of maintaining a healthy appearance done in the privacy and convenience of the home. We were fortunate to have advanced this technology with the help of a partner who invested significant resources along the way in research, development, clinical testing, consumer testing, and patent protection that will make this a reality and ensure that Palomar maintains a leadership position in this innovative technology. We envision a strong market for this OTC device and an increase in consumer awareness that will help drive growth in our professional business.”

About Palomar Medical Technologies Inc:

Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home use, light-based hair removal device. In June 2009, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home use, laser device for the treatment of periorbital wrinkles. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets.

For more information on Palomar and its products, visit Palomar’s website at www.palomarmedical.com. To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the Investor Relations’ section of the website.

    Contacts:  Kerry McAnistan
               Investor Relations Assistant
               Palomar Medical Technologies Inc.
               781-993-2411
               ir@palomarmedical.com

SOURCE: Palomar Medical Technologies Inc.
Kerry McAnistan, Investor Relations Assistant of Palomar Medical Technologies Inc., +1-781-993-2411, ir@palomarmedical.com

               

‘Bunny lines’ can reveal if a person has had Botox

Looking for tell-tale signs of cosmetic surgery on a person’s face has become easier, thanks to the bunny lines that appear after one has had Botox injections. Bunny lines are the subtle crinkly wrinkles on both sides of the nose that often appear as a direct result of Botox-related paralysis, and they get their name from the cute way bunnies scrunch up their noses.

“The most common cause of bunny lines is repeated use of Botox to the glabella, the area between the eyebrows, and forehead region,” the New York Post quoted Park Avenue plastic surgeon Dr. Robert Schwarcz as saying. Read more

               

Next Page »

IAPAM Aesthetic Medicine Resources

• Recent News

  • IAPAM Announces Strong Growth in Botox and Weight Loss
  • Almost Half of Americans Approve of Cosmetic Plastic Surgery Regardless of Income
  • Despite Recession, Overall Plastic Surgery Demand Drops Only 2 Percent From Last Year
  • Body Shaping Companies Announce Co-Marketing and Sales Alliance at American Academy of Dermatology
  • Palomar Medical Presents New Aesthetic Products at the American Academy of Dermatology Annual Meeting
  • BOTOX for Acne
  • Medicis Presents the Dysport(TM) Challenge: Love It or Leave It
  • Allergan Celebrates 20 Years of Approved Use of Botulinum Toxin Type A (BOTOX(R)) in Canada
  • IAPAM Reports on the Best Practices for the use of hCG in Weight Loss
  • hCG in Medically Supervised Weight Loss Programs

Copyright © 2009 Aesthetic Medicine News · Sitemap · Privacy Policy & Terms of Use · Login